Literature DB >> 24620899

Towards a comprehensive Plasmodium falciparum merozoite cell surface and secreted recombinant protein library.

Zenon A Zenonos, Julian C Rayner, Gavin J Wright1.   

Abstract

BACKGROUND: Plasmodium falciparum is the aetiological agent for malaria, a deadly infectious disease for which no vaccine has yet been licensed. The proteins displayed on the merozoite cell surface have long been considered attractive vaccine targets because of their direct exposure to host antibodies; however, progress in understanding the functional role of these targets has been hindered by technical challenges associated with expressing these proteins in a functionally active recombinant form. To address this, a method that enables the systematic expression of functional extracellular Plasmodium proteins was previously developed, and used to create a library of 42 merozoite proteins.
METHODS: To compile a more comprehensive library of recombinant proteins representing the repertoire of P. falciparum merozoite extracellular proteins for systematic vaccine and functional studies, genome-wide expression profiling was used to identify additional candidates. Candidate proteins were recombinantly produced and their integrity and expression levels were tested by Western blotting and ELISA.
RESULTS: Twenty-five additional genes that were upregulated during late schizogony, and predicted to encode secreted and cell surface proteins, were identified and expressed as soluble recombinant proteins. A band consistent with the entire ectodomain was observed by immunoblotting for the majority of the proteins and their expression levels were quantified. By using sera from malaria-exposed immune adults, the immunoreactivity of 20 recombinant proteins was assessed, and most of the merozoite ligands were found to carry heat-labile epitopes. To facilitate systematic comparative studies across the entire library, multiple Plasmodium proteins were simultaneously purified using a custom-made platform.
CONCLUSIONS: A library of recombinant P. falciparum secreted and cell surface proteins was expanded by 20 additional proteins, which were shown to express at usable levels and contain conformational epitopes. This resource of extracellular P. falciparum merozoite proteins, which now contains 62 full-length ectodomains, will be a valuable tool in elucidating the function of these proteins during the blood stages of infection, and facilitate the comparative assessment of blood stage vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24620899      PMCID: PMC3995786          DOI: 10.1186/1475-2875-13-93

Source DB:  PubMed          Journal:  Malar J        ISSN: 1475-2875            Impact factor:   2.979


Background

Plasmodium falciparum is the aetiological agent of the most deadly form of malaria, an infectious tropical disease that accounts for up to one million deaths annually [1,2]. The vast majority of malaria fatalities (85-90%) occur in sub-Saharan Africa, primarily in pregnant women and children under the age of five [2,3]. While anti-malarial drugs exist, the emergence of drug-resistant parasite strains remains a global health concern and no vaccine has been licensed to date. The asexual blood stages of malaria are initiated when a form of the parasite, called a merozoite, invades, replicates and synchronously ruptures host erythrocytes [4] releasing up to 32 progeny merozoites that can invade new erythrocytes. This cyclical phase causes the recurrent fevers and chills that are characteristic of malaria infection [5]. Merozoites are ovoid cells containing apically located secretory organelles that release proteins which are required for the invasion of new erythrocytes [6,7]. While erythrocyte invasion is a rapid process, the brief extracellular exposure of merozoites outside of their intra-erythrocytic niche places them in direct contact with host antibodies, which contribute to naturally acquired immunity to malaria [8,9]; therefore, merozoite cell surface and secreted proteins have long been considered attractive targets for rational vaccine development. The publication of the P. falciparum genome project in 2002 [10] identified the full complement of parasite proteins but progress in understanding the function of these proteins, including those displayed on the merozoite cell surface, has been hindered by the technical difficulties in expressing Plasmodium proteins in a functionally active form [11]. Although the reasons why Plasmodium proteins are difficult to express in heterologous expression systems are not clear, several protein characteristics, such as high molecular mass (>60 kDa), presence of export motifs, and atypical signal peptide sequences negatively impact recombinant expression [12]. In addition, the remarkably high (~80%) A + T content of parasite genes can result in long stretches of repetitive amino acids [13], and codons that are not frequently used by organisms popular for heterologous protein expression. Extracellular vaccine candidates, in particular, present an additional challenge because they often require structurally critical disulfide bonds for correct folding and contain transmembrane domains that make them difficult to solubilize in detergents that retain their native conformation [14-16]. Despite these challenges, recombinant expression of Plasmodium proteins has been attempted in a number of expression systems [12,17] ranging from bacteria [18], yeast [14,19], Dictyostelium discoideum[20], plants and algae [21,22] to mammalian cells [23,24] and cell-free systems [13]. Among them, Escherichia coli is the most popular [17], but the systematic expression of functional P. falciparum proteins remains difficult, with success rates as low as just 6% [25], and often requires subsequent laborious and complex refolding procedures with uncertain outcomes [26]. Consequently, the functional characterization of extracellular parasite proteins has typically been restricted to smaller subfragments that can be expressed rather than the full-length protein or entire ectodomain, which is more likely to be representative of the native protein. The development of a standardized method to express large panels of P. falciparum cell surface and secreted proteins in their native conformation would enable comprehensive protein libraries to be systematically screened in parallel so that direct comparisons between antigens can be made in functional assays such as vaccine screening and immuno-epidemiology studies. To achieve this, Crosnier and colleagues recently developed a method of expressing the entire ectodomains of functional recombinant Plasmodium proteins and used it to compile a large library of 42 proteins [27]. Working towards a comprehensive library of cell surface and secreted P. falciparum merozoite proteins, this manuscript describes the identification and characterization of an additional 20 proteins.

Methods

Recombinant protein design and expression

Proteins were expressed essentially as described previously [27]. Briefly, full-length secreted molecules and the entire ectodomains of membrane-embedded proteins were identified using transmembrane [28], GPI-anchor [29], and signal peptide [30] prediction software. To prevent the inappropriate addition of glycans, which are absent from Plasmodium proteins [31], all potential N-linked glycosylation sites (N-X-S/T, where X is not proline) were systematically mutated by substituting alanine for serine/threonine at these sites. Gene constructs were made by gene synthesis (GeneartAG) using sequences that were codon-optimized for expression in human cells. Protein coding sequences were flanked with unique NotI and AscI restriction sites and subcloned into a derivative of the pTT3 expression plasmid between a 5’ mouse variable κ light chain signal peptide [32], and a 3’ tag consisting of the rat Cd4 domains 3 and 4 followed by an enzymatic biotinylation sequence and a hexahistidine tag [33]. Proteins were expressed as soluble monobiotinylated proteins by transient cotransfection of HEK293E cells with the BirA biotin ligase [34] and harvested six days post transfection [35]. All expression plasmids are openly available from Addgene [36].

Parallel protein purification

His-tagged recombinant merozoite proteins were purified from spent tissue culture supernatants by using a custom-built, piston-driven, sample-loading apparatus as described previously [33]. Briefly, a 96-well His MultiTrap HP filter plate (GE Healthcare) was pre-equilibrated with binding buffer (20 mM sodium phosphate, 40 mM imidazole, 0.5 M NaCl, pH 7.4) at a flow rate of 1 mL/min. The harvested tissue culture supernatants (~200 mL for each protein) were supplemented with imidazole (10 mM) before loading each well at 1 mL/min. The plate was washed with 1.6 mL of binding buffer and proteins eluted with 0.2 mL of elution buffer (20 mM sodium phosphate, 0.4 M imidazole, 0.5 M NaCl, pH 7.4).

Enzyme-linked immunosorbent assay (ELISA)

ELISAs were performed as previously described [37]. Briefly, purified recombinant biotinylated proteins were serially diluted in PBS-T (PBS, 0.1% Tween-20) with 2% BSA, and captured on streptavidin-coated, 96-well plates (NUNC) for one hour before washing and incubating with the anti-Cd4 monoclonal antibody OX68 (1 μg/mL in PBS-T, 2% BSA) for another hour. Plates were washed and incubated with an anti-mouse IgG (Sigma) secondary antibody conjugated to alkaline phosphatase for one hour before further washes and incubation with p-nitrophenyl phosphate (Substrate 104; Sigma) at 1 mg/mL. Absorbance was measured at 405 nm on a PHERAstar plus (BMG Labtech). Concentrations were calculated by comparison to known standards.

Western blotting

Each purified recombinant protein was resolved by SDS-PAGE under reducing conditions before blotting onto Hybond-P PVDF membrane (GE Healthcare) for one hour at 30 V. Membranes were blocked with 2% BSA, in PBS-T and incubated with 0.02 μg/mL of streptavidin-HRP (Jackson Immunoresearch) diluted in PBS-T, 0.2% BSA and detected with the Supersignal West pico chemiluminescent substrate (Pierce).

Immunogenicity study

Proteins were heat treated at 80°C for 10 minutes or left untreated and immobilized on streptavidin-coated, 96-well plates (NUNC), at concentrations sufficient for complete saturation of the available binding surface/well (as determined by ELISA). Following three washes in PBS-T, plates were incubated with pooled sera from malaria-exposed Malawian adults or malaria-naïve UK individuals at a 1:1,000 dilution in PBS-T, 2% BSA followed by an alkaline phosphatase-conjugated anti-human IgG secondary antibody (Sigma) and detected as above.

Results

Identification of candidate Plasmodium falciparum merozoite cell surface and secreted proteins

With the aim of expanding an existing recombinant P. falciparum merozoite cell surface and secreted protein library, publicly available, genome-wide transcription microarray data of P. falciparum intra-erythrocytic stages were analysed [38,39]. To compile a list of merozoite extracellular proteins with possible roles in erythrocyte invasion, the transcription profiles of four well-established P. falciparum merozoite ligands (RH5, AMA1, EBA140, EBA175) that have all been previously implicated in erythrocyte invasion were examined [11,38-41]. It was observed that they all follow a similar expression pattern, passing through a minimum 20 ± 6 hours post invasion and peaking at approximately 42 ± 6 hours after invasion [38,39]. Of the 465 candidate blood stage genes that showed similar expression time windows, 207 encoded a predicted signal peptide and/or a single transmembrane domain/GPI anchor [28-30], suggesting they are likely cell surface or secreted proteins. Multi-pass membrane proteins were excluded from this list because these proteins are unlikely to be expressed in a soluble, secreted form. Within the 207 candidates, 31 were already represented in the existing merozoite library [27] and another 120 were excluded because of their predicted function (e g, involvement in lipid metabolism or nuclear localization) or protein domain content (e g, RNA or DNA binding motif) following gene ontology analysis using PlasmoDB [42], and protein domain mapping using Pfam [43]; also, 42 proteins were excluded due to their large size (>1,400 amino acids). In total, this bioinformatics analysis identified 14 putative secreted or membrane-tethered merozoite proteins. To this list, other members of the MSP3 [44,45], MSP7-like [46-48] and SERA paralogous protein families [49] were added, which were not present in the existing P. falciparum merozoite recombinant protein library [27]. Finally, the available literature was scanned to identify an additional seven merozoite cell surface and secreted proteins [50,51]. In total, 25 putative merozoite secreted or cell surface proteins were chosen for recombinant expression, two of which contained putative GPI anchors, and 23 contained no predicted membrane anchor (Table  1).
Table 1

The putative merozoite cell surface and secreted proteins that were chosen for recombinant expression

NoNameAccession numberTypeRegion targeted for recombinant expressionExp. levels
1¥
rhoptry-associated membrane antigen (RAMA)
MAL7P1.208
GPI
Y17–S840
Medium
2
Prohibitin, putative
PF08_0006
Secreted
L20–F272
Low
3#
Conserved Plasmodium protein, unknown function
PF10_0166
Secreted
Y25–E310
High
4
GLURP
PF10_0344
Secreted
K24–I1233
Low
5
MSP3.5
PF10_0350
Secreted
A20–F710
High
6*
MSP3.6
PF10_0351
Secreted
N22–P566
Medium
7*
MSRP5
PF13_0191
Secreted
N22–I459
Medium
8*
MSRP4
MAL13P1.173
Secreted
D22–Q309
High
9¥
MSP8
PFE0120c
GPI
E26–S576
Low
10#
Conserved Plasmodium protein, unknown function
PF13_0125
Secreted
N20–S292
High
11
Conserved Plasmodium protein, unknown function
PF14_0044
Secreted
Q21–K290
N/D
12
Merozoite-associated tryptophan-rich antigen, putative
PFA0135w
Secreted
I25–K276
High
13
LCCL domain-containing protein
PFA0445w
Secreted
K22–I1029
N/D
14
SERA1
PFB0360c
Secreted
M1–V997
N/D
15¥
SERA2
PFB0355c
Secreted
E23–V1105
Medium
16
SERA3
PFB0350c
Secreted
T23–I930
Medium
17
SERA4
PFB0345c
Secreted
S26–V962
High
18
SERA5
PFB0340c
Secreted
T23–V997
High
19
SERA6
PFB0335c
Secreted
N25–V1031
Low
20¥
SERA7
PFB0330c
Secreted
Q23–V946
Low
21*
SERA9
PFI0135c
Secreted
E23–V932
Medium
22¥
Conserved Plasmodium protein, unknown function
PFA0210c
Secreted
Y24–D466
Low
23
Conserved Plasmodium protein, unknown function
PFB0475c
Secreted
L23–D446
Low
24
Cysteine-rich protective antigen (CyRPA)
PFD1130w
Secreted
D29–E362
High
25RIPRPFC1045cSecretedI20-N1086Low

Protein sequences from 3D7 reference P. falciparum strain were truncated to remove endogenous signal peptides and sequences corresponding to GPI anchors. The region of each protein that was targeted for recombinant expression is shown. Expression levels are given as a guide only because of the significant batch-to-batch variability of transient transfection, and grouped into "high" (between 30 μM and 100 μM after purification), "medium" (1 μM and 30 μM) and "low" (0.01 μM and 1 μM). No detectable expression (N/D) was obtained for PFA0445w, PF14_0044 and SERA1.

¥Proteins selected from [51].

*Proteins included to complete the set of proteins belonging to the MSP3, MSP7-like and SERA families.

#Proteins chosen from [50]. All other proteins were short-listed from bioinformatic analysis of transcription microarray data [38,39]. GPI, GPI-anchored.

The putative merozoite cell surface and secreted proteins that were chosen for recombinant expression Protein sequences from 3D7 reference P. falciparum strain were truncated to remove endogenous signal peptides and sequences corresponding to GPI anchors. The region of each protein that was targeted for recombinant expression is shown. Expression levels are given as a guide only because of the significant batch-to-batch variability of transient transfection, and grouped into "high" (between 30 μM and 100 μM after purification), "medium" (1 μM and 30 μM) and "low" (0.01 μM and 1 μM). No detectable expression (N/D) was obtained for PFA0445w, PF14_0044 and SERA1. ¥Proteins selected from [51]. *Proteins included to complete the set of proteins belonging to the MSP3, MSP7-like and SERA families. #Proteins chosen from [50]. All other proteins were short-listed from bioinformatic analysis of transcription microarray data [38,39]. GPI, GPI-anchored. To design the expression constructs, the entire predicted extracellular domain was selected between the signal sequence and the GPI-anchor, if present. Any predicted N-linked glycosylation sites were systematically removed by substituting alanine for serine/threonine at these sites. Expression constructs were made by gene synthesis and codon optimized for expression in human cells. All expression plasmids are publicly available through Addgene, a not-for-profit, open access plasmid repository [36].

Expression and purification of an expanded Plasmodium falciparum merozoite protein library

All proteins were expressed in HEK293E cells as soluble fusion proteins that contained a C-terminal rat Cd4(d3 + 4)-hexahistidine tag for purification and could be optionally monobiotinylated by cotransfecting a secreted version of the E. coli BirA enzyme [33]. To purify many proteins in parallel for comparative screening, a custom-built protein purification system was employed, that enables the simultaneous purification of up to 96 His-tagged proteins, even from large (>50 mL) tissue culture volumes [33]. Following purification, recombinant proteins were quantitated by ELISA and while expression levels varied significantly between individual proteins, most were purified to micromolar levels (Table  1). Overall, detectable expression was obtained for 22 out of 25 (88%) proteins. Both GLURP and SERA6, although detected by ELISA, were expressed at levels that were too low to include in further analysis and three proteins (PF14_0044, PFA0445w, SERA1) remained undetectable by ELISA despite repeated transfections. To assess their integrity, the recombinant proteins were resolved by SDS-PAGE, and the presence of the C-terminal biotin tag detected by Western blotting (Figure  1). A band consistent with the full-length ectodomain was obtained for 20 out of 25 proteins (80%); in some cases, smaller bands were also evident, most likely due to proteolytic processing. For SERA7 and PF08_0006, bands of ~30 and ~25 kDa were detected, respectively, suggesting complete cleavage at the C-terminus of the protein. Collectively, these observations establish the successful expression of 18/25 (72%) recombinant P. falciparum merozoite proteins at a size consistent with a full-length recombinant protein at usable amounts.
Figure 1

The majority of recombinant merozoite extracellular proteins are expressed at their expected size. One microgram of each purified biotinylated merozoite protein (as estimated by the absorbance at 280 nm) was resolved under reducing conditions by SDS-PAGE, blotted, and probed using streptavidin-HRP. The expected molecular mass of each recombinant protein is indicated in brackets above each lane, including the Cd4-6xHis tag (25 kDa).

The majority of recombinant merozoite extracellular proteins are expressed at their expected size. One microgram of each purified biotinylated merozoite protein (as estimated by the absorbance at 280 nm) was resolved under reducing conditions by SDS-PAGE, blotted, and probed using streptavidin-HRP. The expected molecular mass of each recombinant protein is indicated in brackets above each lane, including the Cd4-6xHis tag (25 kDa).

Members of the recombinant merozoite protein library proteins are immunoreactive and carry heat-labile epitopes

In nature, protective antibodies largely recognize proteins in their native conformation; therefore, to examine whether the recombinant merozoite library proteins were correctly folded, their immunoreactivity against hyperimmune sera from adults living in malaria-endemic regions was tested. All 20 proteins from the library expressed at useable levels were arrayed on a streptavidin-coated, microtitre plate and their relative immunoreactivity to pooled sera from Malawian adults was compared to that from malaria-naïve individuals [52]. All but one (MSRP4) of the proteins were immunoreactive (Figure  2). Strikingly, strong immunoreactivity was observed for most of the SERA proteins, consistent with previous observations [49].
Figure 2

The merozoite recombinant proteins are immunoreactive against hyperimmune sera. The immunoreactivity of the recombinant P. falciparum merozoite proteins was tested using pooled sera from malaria-exposed Malawian adults (red bar) or malaria-naïve adults (green bar). The reduced immunoreactivity of immune sera to heat-denatured antigens (blue bar) demonstrates the presence of heat-labile (conformational) epitopes. All proteins except one (MSRP4) were identified as being immunoreactive as assessed by immunoreactivity >3 SD above negative control (green bar). AMA-1 and Cd4 were used as the positive and negative control, respectively. Data points are shown as mean ± s.d.; n = 3.

The merozoite recombinant proteins are immunoreactive against hyperimmune sera. The immunoreactivity of the recombinant P. falciparum merozoite proteins was tested using pooled sera from malaria-exposed Malawian adults (red bar) or malaria-naïve adults (green bar). The reduced immunoreactivity of immune sera to heat-denatured antigens (blue bar) demonstrates the presence of heat-labile (conformational) epitopes. All proteins except one (MSRP4) were identified as being immunoreactive as assessed by immunoreactivity >3 SD above negative control (green bar). AMA-1 and Cd4 were used as the positive and negative control, respectively. Data points are shown as mean ± s.d.; n = 3. To demonstrate that serum antibodies were recognizing conformational epitopes within the protein library, all recombinant proteins were denatured by heat treatment before being captured via their biotin tag. For 16 of the 20 proteins (all but MSRP4, SERA7, PFA0210c, and PFB0475c) the immunoreactivity decreased significantly when the proteins were heat inactivated, establishing that the antigens contain heat-labile epitopes. These data show that the merozoite recombinant proteins are correctly folded and at least in part mimic the native protein conformation.

Discussion

The technical difficulties in expressing Plasmodium proteins in a recombinant functional form has presented difficulties both for basic malaria research and vaccine development [12]. Here, an approach based on a mammalian expression system has been utilized to significantly expand a recombinant library consisting of recombinant P. falciparum merozoite extracellular proteins from 42 to 62 members [27]. A high-throughput, custom-made purification platform was successfully used to purify recombinant proteins from large volumes of tissue culture supernatants to permit systematic comparative studies of purified antigens [33]. While the overall success rate of expression was high, consistent with previous experience of the HEK293 system [27,53-57], a few merozoite proteins still failed to express, or were expressed at low levels. Although the genes were codon-optimized for human cells, P. falciparum proteins are unusual because they are enriched in asparagine, glutamic acid and lysine, and often contain homopolymeric stretches of amino acids. Indeed, it has been recently demonstrated that the stability of several Plasmodium proteins depends upon their association with heat shock proteins which act as molecular chaperones [58]. Therefore, recombinant protein expression in the HEK293 system could be further enhanced by the presence of PfHsp110c, which has been proposed to be a protein-stabilizing chaperone [58]. Using sera from malaria-immune adults, it has been shown that the expressed recombinant proteins contained heat-labile epitopes suggesting that they adopt their native conformation and are likely to be biochemically active. A number of proteins (e g, PF10_0166, PFA0135w) showed little serological response in comparison to the negative control. While these proteins may not contain epitopes present in the native protein, the possibility that the native proteins are poorly immunogenic and do not induce a strong antibody response in vivo, cannot be excluded. For example, previous studies reported that only 23% of immune sera examined contained specific serum IgG antibodies against PFA0135w, suggesting that this protein does not normally elicit strong humoral responses [59]. Interestingly, RIPR, which binds to PfRH5 [60], is also among the group of generally low responders. PfRH5 is a high priority vaccine target as it plays an essential and universal role in erythrocyte invasion [53,57,61-63], yet it is poorly immunogenic in vivo[61], possibly due to its late release onto the merozoite surface during erythrocyte invasion. RIPR may be similarly masked from the host immune system, but further work with this antigen is clearly required.

Conclusion

A library of recombinant P. falciparum proteins has been expanded and characterized with the eventual aim of compiling a set that is representative of the merozoite surface. These plasmids, which are freely available to the global research community through Addgene [36], will be a valuable resource for basic research and aid the efforts to develop an effective malaria vaccine.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ZAZ, JCR and GJW conceived the study and ZAZ performed the experiments. ZAZ wrote the paper with contributions from JCR and GJW. All authors read and approved the final manuscript.
  61 in total

1.  Action of malarial antibody in vitro.

Authors:  S Cohen; G A Butcher; R B Crandall
Journal:  Nature       Date:  1969-07-26       Impact factor: 49.962

2.  Prediction of potential GPI-modification sites in proprotein sequences.

Authors:  B Eisenhaber; P Bork; F Eisenhaber
Journal:  J Mol Biol       Date:  1999-09-24       Impact factor: 5.469

Review 3.  Production of recombinant proteins from protozoan parasites.

Authors:  José A Fernández-Robledo; Gerardo R Vasta
Journal:  Trends Parasitol       Date:  2010-02-26

4.  Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum.

Authors:  Niraj H Tolia; Eric J Enemark; B Kim Lee Sim; Leemor Joshua-Tor
Journal:  Cell       Date:  2005-07-29       Impact factor: 41.582

5.  A rapid and scalable method for selecting recombinant mouse monoclonal antibodies.

Authors:  Cécile Crosnier; Nicole Staudt; Gavin J Wright
Journal:  BMC Biol       Date:  2010-06-04       Impact factor: 7.431

6.  Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.

Authors:  Nikolay S Outchkourov; Will Roeffen; Anita Kaan; Josephine Jansen; Adrian Luty; Danielle Schuiffel; Geert Jan van Gemert; Marga van de Vegte-Bolmer; Robert W Sauerwein; Hendrik G Stunnenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

7.  PlasmoDB: a functional genomic database for malaria parasites.

Authors:  Cristina Aurrecoechea; John Brestelli; Brian P Brunk; Jennifer Dommer; Steve Fischer; Bindu Gajria; Xin Gao; Alan Gingle; Greg Grant; Omar S Harb; Mark Heiges; Frank Innamorato; John Iodice; Jessica C Kissinger; Eileen Kraemer; Wei Li; John A Miller; Vishal Nayak; Cary Pennington; Deborah F Pinney; David S Roos; Chris Ross; Christian J Stoeckert; Charles Treatman; Haiming Wang
Journal:  Nucleic Acids Res       Date:  2008-10-28       Impact factor: 16.971

8.  Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains.

Authors:  Manuel Llinás; Zbynek Bozdech; Edith D Wong; Alex T Adai; Joseph L DeRisi
Journal:  Nucleic Acids Res       Date:  2006-02-21       Impact factor: 16.971

Review 9.  Heterologous expression of plasmodial proteins for structural studies and functional annotation.

Authors:  Lyn-Marie Birkholtz; Gregory Blatch; Theresa L Coetzer; Heinrich C Hoppe; Esmaré Human; Elizabeth J Morris; Zoleka Ngcete; Lyndon Oldfield; Robyn Roth; Addmore Shonhai; Linda Stephens; Abraham I Louw
Journal:  Malar J       Date:  2008-10-01       Impact factor: 2.979

10.  Biochemical analysis of the Plasmodium falciparum erythrocyte-binding antigen-175 (EBA175)-glycophorin-A interaction: implications for vaccine design.

Authors:  Madushi Wanaguru; Cécile Crosnier; Steven Johnson; Julian C Rayner; Gavin J Wright
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

View more
  15 in total

1.  Strain-Dependent Inhibition of Erythrocyte Invasion by Monoclonal Antibodies Against Plasmodium falciparum CyRPA.

Authors:  Anne S Knudsen; Kasper H Björnsson; Maria R Bassi; Melanie R Walker; Andreas Kok; Bogdan Cristinoi; Anja R Jensen; Lea Barfod
Journal:  Front Immunol       Date:  2021-08-10       Impact factor: 7.561

Review 2.  Plasmodium Parasites Viewed through Proteomics.

Authors:  Kristian E Swearingen; Scott E Lindner
Journal:  Trends Parasitol       Date:  2018-08-23

3.  P-selectin is a host receptor for Plasmodium MSP7 ligands.

Authors:  Abigail J Perrin; S Josefin Bartholdson; Gavin J Wright
Journal:  Malar J       Date:  2015-06-05       Impact factor: 2.979

4.  Quantification of Plasmodium-host protein interactions on intact, unmodified erythrocytes by back-scattering interferometry.

Authors:  Phoonthawee Saetear; Abigail J Perrin; S Josefin Bartholdson; Madushi Wanaguru; Amanda Kussrow; Darryl J Bornhop; Gavin J Wright
Journal:  Malar J       Date:  2015-02-21       Impact factor: 2.979

5.  Computational prediction of protein interactions related to the invasion of erythrocytes by malarial parasites.

Authors:  Xuewu Liu; Yuxiao Huang; Jiao Liang; Shuai Zhang; Yinghui Li; Jun Wang; Yan Shen; Zhikai Xu; Ya Zhao
Journal:  BMC Bioinformatics       Date:  2014-11-30       Impact factor: 3.169

6.  Serological markers to measure recent changes in malaria at population level in Cambodia.

Authors:  Karen Kerkhof; Vincent Sluydts; Laura Willen; Saorin Kim; Lydie Canier; Somony Heng; Takafumi Tsuboi; Tho Sochantha; Siv Sovannaroth; Didier Ménard; Marc Coosemans; Lies Durnez
Journal:  Malar J       Date:  2016-11-04       Impact factor: 2.979

7.  P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5.

Authors:  Francis Galaway; Laura G Drought; Maria Fala; Nadia Cross; Alison C Kemp; Julian C Rayner; Gavin J Wright
Journal:  Nat Commun       Date:  2017-02-10       Impact factor: 14.919

8.  KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization.

Authors:  Gathoni Kamuyu; James Tuju; Rinter Kimathi; Kennedy Mwai; James Mburu; Nelson Kibinge; Marisa Chong Kwan; Sam Hawkings; Reuben Yaa; Emily Chepsat; James M Njunge; Timothy Chege; Fatuma Guleid; Micha Rosenkranz; Christopher K Kariuki; Roland Frank; Samson M Kinyanjui; Linda M Murungi; Philip Bejon; Anna Färnert; Kevin K A Tetteh; James G Beeson; David J Conway; Kevin Marsh; Julian C Rayner; Faith H A Osier
Journal:  Front Immunol       Date:  2018-12-11       Impact factor: 7.561

9.  Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens.

Authors:  Joseph J Illingworth; Daniel G Alanine; Rebecca Brown; Jennifer M Marshall; Helen E Bartlett; Sarah E Silk; Geneviève M Labbé; Doris Quinkert; Jee Sun Cho; Jason P Wendler; David J Pattinson; Lea Barfod; Alexander D Douglas; Michael W Shea; Katherine E Wright; Simone C de Cassan; Matthew K Higgins; Simon J Draper
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

10.  A library of recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and reverse vaccinology.

Authors:  Catherine M Elton; Marilis Rodriguez; Choukri Ben Mamoun; Cheryl A Lobo; Gavin J Wright
Journal:  Int J Parasitol       Date:  2018-10-24       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.